Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Linda Opanga, Mercy N. Mulaku, Sylvia A. Opanga, Brian Godman & Amanj Kurdi. (2019) Adverse effects of chemotherapy and their management in Pediatric patients with Non-Hodgkin’s Lymphoma in Kenya: A descriptive, situation analysis study. Expert Review of Anticancer Therapy 19:5, pages 423-430.
Read now
Read now
Ilse Van Horebeek, Noël Knops, Maria Van Dyck, Elena Levtchenko & Djalila Mekahli. (2017) Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature. Acta Clinica Belgica 72:3, pages 147-155.
Read now
Read now
Randeep Sangha, Andrew Davies, Nam H. Dang, Michinori Ogura, David A. MacDonald, Revathi Ananthakrishnan, M. Luisa Paccagnella, Erik Vandendries, Joseph Boni & Yeow Tee Goh. (2017) Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. Journal of Drug Assessment 6:1, pages 10-17.
Read now
Read now
Andrea Janikova, Zbynek Bortlicek, Vit Campr, Natasa Kopalova, Katerina Benesova, Jitka Hamouzova, David Belada, Vit Prochazka, Robert Pytlik, Samuel Vokurka, Jan Pirnos, Juraj Duras, Heidi Mocikova, Jiri Mayer & Marek Trneny. (2016) Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database. Leukemia & Lymphoma 57:5, pages 1094-1103.
Read now
Read now
Nadia Mensali, Fan Ying, Vincent Oei Yi Sheng, Weiwen Yang, Even Walseng, Shraddha Kumari, Lars-Egil Fallang, Arne Kolstad, Wolfgang Uckert, Karl Johan Malmberg, Sébastien Wälchli & Johanna Olweus. (2016) Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA. OncoImmunology 5:5.
Read now
Read now
Andrea Janikova, Zbynek Bortlicek, Vit Campr, Natasa Kopalova, Katerina Benesova, David Belada, Vit Prochazka, Robert Pytlik, Samuel Vokurka, Jan Pirnos, Juraj Duras, Heidi Mocikova, Jiri Mayer & Marek Trneny. (2015) Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?. Leukemia & Lymphoma 56:8, pages 2350-2356.
Read now
Read now
Joseph Adrian Lumawig Buensalido & Pranatharthi H Chandrasekar. (2014) Prophylaxis against hepatitis B reactivation among patients with lymphoma receiving rituximab. Expert Review of Anti-infective Therapy 12:2, pages 151-154.
Read now
Read now
Articles from other publishers (40)
Prerna Sharma, Rahul V. Joshi, Robert Pritchard, Kevin Xu & Maya A. Eicher. (2023) Therapeutic Antibodies in Medicine. Molecules 28:18, pages 6438.
Crossref
Crossref
Eric S. Geanes, Stacey A. Krepel, Rebecca McLennan, Stephen Pierce, Santosh Khanal & Todd Bradley. (2022) Development of combinatorial antibody therapies for diffuse large B cell lymphoma. Frontiers in Medicine 9.
Crossref
Crossref
Rita Tavarozzi & Enrica Manzato. (2022) The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use. Antibodies 11:1, pages 16.
Crossref
Crossref
Lukas Uhrik, Lenka Hernychova, Petr Muller, Umesh Kalathiya, Malgorzata M. Lisowska, Mikolaj KocikowskiMaciej ParysJakub Faktor, Marta Nekulova, Chris NortcliffePavlina Zatloukalova, Barbara Ruetgen, Robin Fahraeus, Kathryn L. BallDavid J. ArgyleBorivoj Vojtesek & Ted R. Hupp. (2021) Hydrogen deuterium exchange mass spectrometry identifies the dominant paratope in CD20 antigen binding to the NCD1.2 monoclonal antibody. Biochemical Journal 478:1, pages 99-120.
Crossref
Crossref
Jaclyn L.F. Bosco & Priscilla Velentgas. 2021. Pragmatic Randomized Clinical Trials. Pragmatic Randomized Clinical Trials
361
386
.
Robert Pytlik, Kamila Polgarova, Jana Karolova & Pavel Klener. (2020) Current Immunotherapy Approaches in Non-Hodgkin Lymphomas. Vaccines 8:4, pages 708.
Crossref
Crossref
Hiroaki Tanaka, Naoki Kaneko, Hideki Sakagami, Takahiro Matsuya, Masashi Hiramoto, Yosuke Yamanaka, Masamichi Mori, Hiroyuki Koshio, Masaaki Hirano & Masahiro Takeuchi. (2020) Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma. Leukemia Research 88, pages 106286.
Crossref
Crossref
Russell Reeve, Seth Berry & Brandon Swift. 2020. Quantitative Methods in Pharmaceutical Research and Development. Quantitative Methods in Pharmaceutical Research and Development
409
445
.
Marcela Osovská, Andrea Janíková, Leoš Křen & Andrea Marečková. (2019) Chronic Benign CD8+ Proliferation: A Rare Affection that Can Mimic a Lymphoma Relapse. Case Reports in Hematology 2019, pages 1-4.
Crossref
Crossref
Christian S. Backes, Kim S. Friedmann, Sebastian Mang, Arne Knörck, Markus Hoth & Carsten Kummerow. (2018) Natural killer cells induce distinct modes of cancer cell death: Discrimination, quantification, and modulation of apoptosis, necrosis, and mixed forms. Journal of Biological Chemistry 293:42, pages 16348-16363.
Crossref
Crossref
John Zalcberg. (2018) Biosimilars are coming: ready or not. Internal Medicine Journal 48:9, pages 1027-1034.
Crossref
Crossref
Marcel Reiser, Steffen Dörfel, Manfred Hensel, Mark Hoesl, Wolf-Oliver Jordan, Michael Koenigsmann, Dirk Meyer, Dietmar Reichert, Andreas Schwarzer, Moritz Marquardt, Kerstin Kellershohn & Kathleen Jentsch-Ullrich. (2018) Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice. European Journal of Haematology 100:5, pages 455-464.
Crossref
Crossref
. 2018. Post-Authorization Safety Studies of Medicinal Products. Post-Authorization Safety Studies of Medicinal Products
253
327
.
Stewart Sell. (2017) Cancer immunotherapy: Breakthrough or “deja vu, all over again”?. Tumor Biology 39:6, pages 101042831770776.
Crossref
Crossref
Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, Andrew Davies, Michael Crump, Revathi Ananthakrishnan, Taro Ishibashi, M. Luisa Paccagnella, Joseph Boni, Erik Vandendries & David MacDonald. (2016) Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research 22:19, pages 4807-4816.
Crossref
Crossref
C. Demoor-Goldschmidt, P. Agape, I. Barillot & M.A. Mahé. (2016) Radiothérapie des lymphomes malins non hodgkiniens ganglionnaires folliculaires et diffus de stade limité. Cancer/Radiothérapie 20:6-7, pages 530-534.
Crossref
Crossref
M. Lepetit & D.-A. Laplaud. (2016) Effetti collaterali delle bioterapie nella sclerosi multipla e nelle malattie correlate. EMC - Neurologia 16:3, pages 1-10.
Crossref
Crossref
Arati A. Inamdar, Andre Goy, Nehad M. Ayoub, Christen Attia, Lucia Oton, Varun Taruvai, Mark Costales, Yu-Ting Lin, Andrew Pecora & K. Stephen Suh. (2016) Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents. Oncotarget 7:30, pages 48692-48731.
Crossref
Crossref
Richard Greil, Petra Obrtlíková, Lukáš Smolej, Tomáš Kozák, Michael Steurer, Johannes Andel, Sonja Burgstaller, Eva Mikušková, Liana Gercheva, Thomas Nösslinger, Tomáš Papajík, Miriam Ladická, Michael Girschikofsky, Mikuláš Hrubiško, Ulrich Jäger, Michael Fridrik, Martin Pecherstorfer, Eva Králiková, Cristina Burcoveanu, Emil Spasov, Andreas Petzer, Georgi Mihaylov, Julian Raynov, Horst Oexle, August Zabernigg, Emília Flochová, Stanislav Palášthy, Olga Stehlíková, Michael Doubek, Petra Altenhofer, Lisa Pleyer, Thomas Melchardt, Anton Klingler, Jiří Mayer & Alexander Egle. (2016) Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. The Lancet Haematology 3:7, pages e317-e329.
Crossref
Crossref
Tarik Hadid, Ali Raufi, Zyad Kafri, Mary Mandziara, John Kalabat, Susan Szpunar, Kleanthe Kolizeras, Mary Steigelman & Ayad Al-Katib. (2016) Safety and efficacy of radioimmunotherapy (RIT) in treatment of non-Hodgkin's lymphoma in the community setting. Nuclear Medicine and Biology 43:4, pages 227-231.
Crossref
Crossref
Morton Coleman, Philip E. Lammers, Fabio Ciceri & Ira A. Jacobs. (2016) Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 16:4, pages 175-181.
Crossref
Crossref
Saurabh Jain, Luca Aresu, Stefano Comazzi, Jianguo Shi, Erin Worrall, John Clayton, William Humphries, Sandra Hemmington, Paul Davis, Euan Murray, Asmare A. Limeneh, Kathryn Ball, Eva Ruckova, Petr Muller, Borek Vojtesek, Robin Fahraeus, David Argyle & Ted R. Hupp. (2016) The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine. PLOS ONE 11:2, pages e0148366.
Crossref
Crossref
Hiroshi Ureshino, Atsujiro Nishioka, Kensuke Kojima, Motoaki Suzuki, Haruna Kizuka, Haruhiko Sano, Takero Shindo, Yasushi Kubota, Toshihiko Ando & Shinya Kimura. (2016) Rituximab-induced Acute Thrombocytopenia in High Tumor Burden Follicular Lymphoma. Internal Medicine 55:15, pages 2061-2064.
Crossref
Crossref
Perry Tsai, William O Thayer, Liqin Liu, Guido Silvestri, Jeffrey L Nordstrom & J Victor Garcia. (2016) CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice. Molecular Therapy - Oncolytics 3, pages 15024.
Crossref
Crossref
Gaetano Romano. (2015) Tumor markers currently utilized in cancer care. Materials and Methods 5.
Crossref
Crossref
Michael Herold, Christian W. Scholz, Frank Rothmann, Carsten Hirt, Volker Lakner & Ralph Naumann. (2015) Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma. Journal of Cancer Research and Clinical Oncology 141:9, pages 1689-1695.
Crossref
Crossref
Hirotaka Tomiyasu & Hajime Tsujimoto. (2015) Comparative Aspects of Molecular Mechanisms of Drug Resistance through ABC Transporters and Other Related Molecules in Canine Lymphoma. Veterinary Sciences 2:3, pages 185-205.
Crossref
Crossref
Agustin AvilèsMaria-Jesùs NamboJudith Huerta-GuzmànLuis SilvaNatividad Neri. (2015) Rituximab as Consolidation Therapy Did Not Improve Outcome in Patients with Diffuse Large B-Cell Lymphoma at Complete Response After Dose-Dense Chemotherapy (CHOP-14). Cancer Biotherapy and Radiopharmaceuticals 30:3, pages 107-110.
Crossref
Crossref
David J. Straus, Paul A. Hamlin, Matthew J. Matasar, Maria Lia Palomba, Pamela R. Drullinsky, Andrew D. Zelenetz, John F. Gerecitano, Ariela Noy, Audrey M. Hamilton, Rebecca Elstrom, Brett Wegner, Katy Wortman & David Cella. (2015) Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. British Journal of Haematology 168:5, pages 663-670.
Crossref
Crossref
Kim L Brunekreeft, Corinna Strohm, Marloes J Gooden, Anna A Rybczynska, Hans W Nijman, Götz U Grigoleit, Wijnand Helfrich, Edwin Bremer, Daniela Siegmund, Harald Wajant & Marco de Bruyn. (2014) Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death. Molecular Cancer 13:1.
Crossref
Crossref
Claire Fabre, Marco Gobbi, Cyrine Ezzili, Mustapha Zoubir, Marie-Paule Sablin, Karen Small, Ellie Im, Nabeegha Shinwari, Da Zhang, Honghong Zhou & Christophe Le Tourneau. (2014) Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemotherapy and Pharmacology 74:5, pages 1057-1064.
Crossref
Crossref
Cundong Jia, Liping Liang, Lili Yang, Feng Zhao & Jingping Bai. (2014) Expression levels of TWIST1 are associated with the clinicopathological stage of B‑cell non‑Hodgkin lymphoma. Experimental and Therapeutic Medicine.
Crossref
Crossref
S-H Kuo, K-H Yeh, L-T Chen, C-W Lin, P-N Hsu, C Hsu, M-S Wu, Y-S Tzeng, H-J Tsai, H-P Wang & A-L Cheng. (2014) Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity. Blood Cancer Journal 4:6, pages e220-e220.
Crossref
Crossref
Grzegorz Terszowski, Christian Klein & Martin Stern. (2014) KIR/HLA Interactions Negatively Affect Rituximab- but Not GA101 (Obinutuzumab)-Induced Antibody-Dependent Cellular Cytotoxicity. The Journal of Immunology 192:12, pages 5618-5624.
Crossref
Crossref
Venkat Reddy & Maria Leandro. (2014) Variability in clinical and biological response to rituximab in autoimmune diseases: an opportunity for personalized therapy?. International Journal of Clinical Rheumatology 9:3, pages 279-293.
Crossref
Crossref
Tom Eyckmans, Elke Wollants, Ann Janssens, Hélène Schoemans, Katrien Lagrou, Joost Wauters & Johan Maertens. (2014) Coxsackievirus A16 Encephalitis during Obinutuzumab Therapy, Belgium, 2013. Emerging Infectious Diseases 20:5, pages 913-915.
Crossref
Crossref
Tali Siegal. (2014) Primary central nervous system lymphoma: Current state of anti-CD20 therapy and appraisal of reported response criteria. Journal of Clinical Neuroscience 21:5, pages 709-715.
Crossref
Crossref
Verena Strassberger, Katrin L. Gutbrodt, Nikolaus Krall, Christoph Roesli, Hitoshi Takizawa, Markus G. Manz, Tim Fugmann & Dario Neri. (2014) A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development. Journal of Proteomics 99, pages 138-151.
Crossref
Crossref
Noriaki Kawano, Nobuyuki Ono, Sayaka Kawano, Takuro Kuriyama, Shuro Yoshida, Sanshiro Inoue, Kiyoshi Yamashita, Daisuke Himeji, Yoshiya Shimao, Kousuke Marutsuka, Koichi Oshima, Akira Ueda & Fumiko Kawano. (2014) Clinical Features and Outcomes of 9 Patients with Immunodeficiency-Associated Lymphoproliferative Disorders Treated at a Single Institution. Journal of Clinical and Experimental Hematopathology 54:3, pages 187-196.
Crossref
Crossref
Knut Bjøro Smeland, Cecilie E. Kiserud, Grete F. Lauritzsen, Anne Kirsti Blystad, Unn Merete Fagerli, Øystein Fluge, Alexander Fosså, Jens Hammerstrøm, Arne Kolstad, Jon Håvard Loge, Martin Maisenhølder, Bjørn Østenstad, Stein Kvaløy & Harald Holte. (2013) Høydosebehandling med autolog stamcellestøtte ved lymfom i Norge 1987 – 2008. Tidsskrift for Den norske legeforening 133:16, pages 1704-1709.
Crossref
Crossref